Moleculin Biotech is trading 29.94% down now at $0.54 after investors reacted to Nasdaq’s September 15, 2026 staff determination, disclosed September 18, 2026.
- Shares stayed below Nasdaq’s $1.00 minimum bid requirement for 30 consecutive business days, violating Listing Rule 5550(a)(2).
- Nasdaq denied the standard 180-day cure period because of a recent reverse split; Moleculin plans to request a hearing, which would temporarily stay delisting action.
- The broader market is higher on September 21, 2026, indicating the decline is company-specific rather than a broad risk-off move.